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Abstract
Introduction: Anidulafungin is a new echinocandin antifungal agent with indications for use in esophageal candidiasis and candidemia.
The mortality and morbidity associated with fungal infections in healthcare facilities necessitates the development of new treatment
options for these diseases.
Aims: This review assesses the pharmacology and evidence for the use of anidulafungin in the treatment of serious fungal infections.
Evidence review: There is substantial evidence that anidulafungin is a potent antifungal agent with activity against a broad range of
fungal species. Likewise, evidence supports that anidulafungin is a well-tolerated antifungal agent. Clinical studies provide sufficient
evidence for regulatory approval for esophageal candidiasis and candidemia, and limited evidence suggests that anidulafungin may be
superior to fluconazole for candidemia and invasive candidiasis. The introduction of anidulafungin into clinical practice adds a third
option for therapy in the echinocandin class. Research into its efficacy in other fungal infections is ongoing, and further studies into the
impact of anidulafungin on economic outcomes will be beneficial.
Place in therapy: Current evidence supports the use of anidulafungin in the management of candidemia, esophageal candidiasis, and
invasive candidiasis, as demonstrated by the successful results in large multicenter clinical trials.
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Core evidence place in therapy summary for anidulafungin in candidiasis
Outcome measure Evidence Implications
Disease-oriented evidence
Microbiologic response Clear Achieved in the majority of patients with few episodes of invasive infection
Patient-oriented evidence
Clinical response Clear Effective
Few drug-induced adverse events Substantial Safe and easy to use, and well tolerated, with low discontinuation rates
No drug–drug interactions Clear Safe and easy to use in patients on numerous medicationsScope, aims, and objectives
Anidulafungin is one of several drugs in the echinocandin class
of antifungal agents. This evidence-based review focuses on the
pharmacology and place in therapy for anidulafungin, the newest
of the echinocandin antifungal agents. There have been several
prior reviews on anidulafungin within the last few years (Murdoch
& Plosker 2004; Pfaller 2004; Raasch 2004; Vazquez 2005;
Vazquez 2006a,b; Vazquez & Sobel 2006). Most reviews,
however, were published prior to the presentation of the data
from the last two clinical trials performed with anidulafungin. In
addition, this review utilizes evidence-based medical data in an
attempt to identify anidulafungin’s place in the antifungal
armamentarium. Anidulafungin is the most recent addition to the
echinocandin class of antifungals, which includes caspofungin
and micafungin (Table 1).
Methods
Searches of English language medical literature were conducted
between May 1 and May 5, 2007, and November 1–9, 2007 in the
following databases:
• PubMed, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi, 1966
to date
• American Society for Microbiology abstract database,
http://www.abstracts2view.com/icaac
• http://www.antimicrobe.org
• http://www.doctorfungus.org
• http://www.merck.com/product/usa/pi_circulars/c/cancidas/
cancidas_pi.pdf
• http://www.pfizer.com/pfizer/download/uspi_eraxis.pdf
• http://www.astellas.us/docs/mycamine.pdf
The search terms utilized included “anidulafungin,”
“caspofungin,” “micafungin,” “Eraxis,” “Cancidas,” “Mycamine,”
“echinocandins,” “candidemia,” “candidiasis,” “esophageal
candidiasis,” “LY 303366,” and “VER-002.” The literature search
results are shown in Table 2.
Disease overview
Invasive fungal infections are of increasing importance in
hospitalized patients, both with and without underlying
immunocompromise. Over the past decade the frequency and
diversity of invasive fungal infections has dramatically increased.
Infections due to Candida species are currently the fourth most
common cause of bloodstream infections (Wisplinghoff et al.
2004), while invasive aspergillosis has become the most
common serious mold infection in immunocompromised hosts
(Denning et al. 1998). While infections with Aspergillus species
present significant diagnostic and therapeutic challenges with
considerable morbidity, mortality, and cost, it is clear that
infections due to Candida spp. are much more commonly
observed in hospitalized patents. Serious Candida infections
may range from primary bloodstream infections and catheter-
related infections to disseminated candidiasis, where
candidemia may not be apparent. The attributable mortality rates
are difficult to estimate; crude mortality rates range from 30–60%
(Zaoutis et al. 2005).
Current therapy options
Recent literature has shown that early initiation of antifungal
therapy can improve patient outcomes, and considerable
research is ongoing to define optimal therapy (Garey et al. 2006;
Davis et al. 2007).
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Category Number of records
Full papers Abstracts
Initial search 89 11
records excluded 33 6
records included 56 5
Level 1 clinical evidence 20
Level 2 clinical evidence 2 2
Level ≥3 clinical evidence 42
trials other than RCT 46 1
case studies 20
Economic evidence 00
For definitions of levels of evidence, see Editorial Information on inside back cover or on
Core Evidence website (http://www.coremedicalpublishing.com).
RCT, randomized controlled trial.
Table 2 | Evidence base included in the review
Indication Anidulafungin Caspofungin Micafungin
Esophageal candidiasis FDA
approved
FDA
approved
FDA
approved
Candidemia and other
forms of Candida infection
(intra-abdominal abscess
and peritonitis)a
FDA
approved
FDA
approved
Empirical therapy for
presumed fungal
infections in febrile
neutropenic patients
FDA
approved
Invasive aspergillosis in
patients who are refractory
to or intolerant of other
therapiesb
FDA
approved
Prophylaxis of Candida
infections in patients
undergoing hematopoietic
stem cell transplantation
FDA
approved
aCaspofungin is also indicated for treatment of pleural space infections.
bCaspofungin has not been studied as initial therapy for invasive aspergillosis.
FDA, Food and Drug Administration.
Table 1 | FDA-approved indications of available echinocandin
antifungals (Eraxisﾮ prescribing information;
Cancidasﾮ prescribing information; Mycamineﾮ
prescribing information)243
Guidelines for the management of candidemia and candidiasis
have been published by the Mycosis Study Group and Infectious
Disease Society of the Americas and can be accessed via the
website www.idsociety.org (Pappas et al. 2004). For several
decades, amphotericin B was the only antifungal agent available
for the treatment of systemic fungal infections. However, over the
past 10–15 years several new classes of antifungals, specifically
the azoles (fluconazole, itraconazole, voriconazole,
posaconazole) and the echinocandins (caspofungin, micafungin,
anidulafungin) are now available to manage these severe
infections. For the past decade, fluconazole has been the main
antifungal used to treat candidal infections in most types of
patients. Unfortunately, over the past decade, two major changes
have occurred that have precipitated a change in the
management of candidal infections. The first change has been a
well-documented shift in the Candida species causing
candidemia and candidiasis, from the susceptible Candida
albicans, to the less susceptible nonalbicans Candida (NAC)
species. Of the NAC species, C. glabrata, C. parapsilosis,
C. tropicalis, and C. krusei constitute the bulk of infections. These
NAC species are important because they have varying
susceptibilities to azoles and amphotericin B. The second change
has been the development of fluconazole resistance in some of
the NAC species, especially C. glabrata. The changing
epidemiology of fungal infections coupled with the significant
mortality and cost associated with the treatment of fungal
infection has driven the development of new antifungal agents.
Although new guidelines are under development, the current
recommendation is to initiate antifungal therapy with either
fluconazole, one of the echinocandins, or voriconazole,
depending on the species of Candida identified in the patient
(Pappas et al. 2004). In patients that are hemodynamically
unstable, neutropenic, or infected with either C. glabrata or
C. krusei the echinocandins are the preferred antifungal agents.
Unmet needs
Despite the availability of several new antifungal agents, the
attributable mortality rates associated with candidemia and
invasive candidiasis are generally between 30–40%, and have
remained unchanged for the past decade. In addition, because of
the extensive amount of fluconazole use in clinical practice over
the past 10–15 years, we now have to recognize the increased
frequency of azole resistance in the NAC species, especially in
C. glabrata. These two reasons are why the echinocandins
(caspofungin, micafungin, and anidulafungin) have become the
preferred antifungal agents in seriously ill patients with
disseminated fungal infections.
Anidulafungin pharmacology
Chemistry and mechanism
Echinocandin antifungals were first discovered in the 1970s, and
named the pneumocandins for their activity against Pneumocystis
(Denning 1997). Approved by the FDA in 2006, anidulafungin was
the first echinocandin discovered; however, caspofungin and
micafungin were introduced into the market in 2001 and 2005,
respectively. Anidulafungin is derived from echinocandin B0,
which is produced by A. nidulans. Anidulafungin’s structure
consists of an amphiphilic hexapeptide linked to an
alcoxytriphenyl side chain. It is this N-linked acyl lipid side chain
that differs between the echinocandins, and accounts for some of
the differences in their properties (Kurtz & Rex 2001). Drugs in the
echinocandin class of antifungals inhibit cell wall synthesis,
causing cell wall damage through noncompetitive inhibition of
beta-(1,3)-glucan-synthase (Douglas 2001). Depletion of beta-
(1,3)-glucan, a vital component of the fungal cell wall structure,
leads to osmotic cell lysis.
Pharmacodynamics
Anidulafungin demonstrates in-vitro activity against many
clinically relevant fungal species including a broad range of
Candida species, such as those strains resistant to fluconazole or
amphotericin B. In-vitro susceptibility assays reveal a decreased
activity against C. parapsilosis, although no direct correlation
between minimum inhibitory concentration (MIC) and clinical
outcome has been established for echinocandins (Table 3) (Marco
et al. 1998; Uzun et al. 1997; Zhanel et al. 1997; Wiederhold et al.
2003; Pfaller et al. 2005; Pfaller et al. 2006). Furthermore,
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Anidulafungin Caspofungin Micafungin
AUC
(mcg/h per mL)
110
(100 mg dose)
98
(70 mg dose)
66
(75 mg dose)
Candida albicans
MIC range 0.007–2 0.007–0.5 0.007–0.25
MIC50 0.03 0.03 0.015
MIC90 0.06 0.06 0.03
C. parapsilosis
MIC range 0.015–4 0.015–4 0.015–2
MIC50 2 0.5 1
MIC90 2 1 2
C. glabrata
MIC range 0.06–0.25 0.015–8 0.007–1
MIC50 0.12 0.03 0.015
MIC90 0.25 0.06 0.015
C. krusei
MIC range 0.125–0.5 0.015–1 0.015–0.25
MIC50 0.25 0.06 0.006
MIC90 0.25 1 0.12
Aspergillus fumigatus
MIC range <0.03–0.06 0.015–2 0.007–0.015
A. flavus MIC range <0.03–0.12 0.015–0.12 0.007–0.015
A. terreus MIC range 0.03 0.12–2.0 0.003–0.007
A. niger MIC range 0.03–0.125 0.12–2.0 0.007–0.015
Table 3 | Minimum inhibitory concentrations (MIC) of
echinocandin antifungals against Candida species
and various molds (Vazquez et al. 1997; Marco et al.
1998; Uzun et al. 1997; Zhanel et al. 1997; Espinel-
Ingroff 1998; Tawara et al. 2000; Wiederhold et al.
2003; Pfaller et al. 2005; Pfaller et al. 2006)anidulafungin also has proven in-vitro activity against
fluconazole- and itraconazole-resistant Candida species
recovered from HIV-positive individuals (Chavez et al. 1999;
Cuenca-Estrella et al. 2000; Pfaller et al. 2005). Anidulafungin
has also demonstrated in-vitro activity against Aspergillus
species including A. fumigatus, A. flavus, A. niger, and
A. terreus, along with activity against many of the emerging
molds such as Bipolaris spicifera, Exophiala jeanselmei,
Fonsecaea pedrosoi, Madurella mycetomatis, Penicillium
marneffei, Phialophora verrucosa, Pseudallescheria boydii,
Sporothrix schenckii, and Wangiella dermatitidis (Espinel-Ingroff
1998; Odabasi et al. 2004).
In addition, anidulafungin has demonstrated additive effects in
combination with amphotericin B against Aspergillus and
Fusarium species, and potential synergistic activity in
combination with itraconazole or voriconazole against
Aspergillus species (Philip A et al. 2005; Vazquez 2007).
The pharmacodynamic activity of anidulafungin (like other
echinocandins) differs between organisms. Against Aspergillus,
anidulafungin exerts a fungistatic effect in vivo, and
demonstrates fungicidal activity against Candida species in vitro
and in vivo. Against Candida species, the effect of
echinocandins has been shown to be related to concentration
and area under the concentration-time curve (Petraitiene et al.
1999; Louie et al. 2005). Additionally, an Eagle-like effect
(paradoxical increase in fungal growth at higher concentrations)
has been observed in yeast and filamentous fungi; however
additional investigation into the mechanism and clinical
significance of this relationship is warranted (Clemons &
Stevens 2006; Wiederhold et al. 2004). In-vitro assays of
anidulafungin in the presence of human serum suggest that
serum binding reduces the activity of echinocandins against
glucan synthase (Paderu et al. 2007). The clinical significance of
the high protein binding is currently not known.
Resistance
The definition of echinocandin resistance is yet to be defined, but
recent Clinical and Laboratory Standards Institute guidelines
define a susceptible isolate with an MIC of <2 mcg/mL as
susceptible, and isolates with MICs to echinocandins of
>2 mcg/mL as nonsusceptible. To date, reduced echinocandin
susceptibility remains uncommon, although most of the research
to date has evaluated caspofungin susceptibility and reduced
susceptibility. There have been several reports describing cross-
resistance of echinocandins in different Candida species after
prolonged exposures to echinocandins (Hakki et al. 2006;
Laverdiere et al. 2006). In addition, in one series, although the
activity was compromised, anidulafungin retained greater activity
among C. glabrata isolates with reduced caspofungin
susceptibility (Cota et al. 2006). In a recent case report by
Moudgal et al., the authors described the first case of a
multiechinocandin-resistant C. parapsilosis infection in a patient
with refractory prosthetic valve endocarditis (Moudgal et al. 2005).
Interestingly enough, all of the isolates that demonstrated
reduced susceptibility to caspofungin and micafungin remained
susceptible to anidulafungin. More recently, Chen et al. (2005)
described 31 isolates of C. parapsilosis recovered from burn unit
patients that displayed reduced susceptibility to micafungin and
or caspofungin, but retained their susceptibility to anidulafungin.
The mechanism of this cross-reduced echinocandin susceptibility
is currently unknown.
Although the mechanisms of resistance to the echinocandins
are not yet fully understood, there are several mechanisms that
have been recently elucidated and reported. The most
commonly described mechanisms involve the FKS1 and FKS2
genes that encode for the catalytic subunit of beta-(1,3)-glucan
synthase (Douglas 2001; Douglas et al. 1994). Several
investigators have already described mutations in two different
“hotspots” of the FKS1 gene that have been shown to confer
resistance to caspofungin in C. albicans, C. glabrata, and
C. guilliermondii (Park et al. 2005; Balashov 2006; Katiyar 2006;
Miller 2006). Other purported resistance mechanisms are the
overproduction of beta-(1,3)-glucan synthase and the
expression of efflux pumps (Osherov et al. 2002; Ghannoum
2005). Echinocandins have no activity against Cryptococcus
neoformans, possibly related to impaired binding to a
variation of glucan synthase in this organism (Maligie &
Selitrennikoff 2006).
Pharmacokinetics
Like other echinocandins, oral bioavailability of anidulafungin is
less than 10%, and thus is only available for parenteral
administration. Protein binding was originally reported to be
84% (Wiederhold & Lewis 2003); however, it is now believed to
be approximately 98%, which is consistent with the other
agents in the class (Eraxis prescribing information).
Anidulafungin demonstrates a large volume of distribution of
30–50L, and a terminal elimination half-life of 25 hours, following
a biexponential decay. Steady-state concentrations are
achieved on the first day of therapy after administration of a
loading dose twice the normal daily dose. Anidulafungin is not
metabolized by the liver, but undergoes slow chemical
degradation by peptidases. An intermediate metabolite is
formed by the opening of the hexapeptide ring, and this is then
metabolized in plasma to tertiary degradation products.
Approximately 10% of anidulafungin is eliminated unchanged
via the biliary system. Since the drug is not degraded by hepatic
enzymes, there are no interactions with the cytochrome
P450 system.
Few data exist on anidulafungin in pediatric patients; however,
an evaluation of safety and pharmacokinetics was conducted in
a group of neutropenic children 2–17 years of age. A total of
24 patients were administered 0.75 mg/kg per day or 1.5 mg/kg
per day anidulafungin based on total body weight, and
pharmacokinetic parameters were determined. The study
excluded children with hepatic or renal disease. The
investigators determined that pediatric patients receiving
0.75 mg/kg per day or 1.5 mg/kg per day achieved similar
anidulafungin concentrations to adults receiving 50 or
100mg/day, respectively (Benjamin 2006).
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Clinical evidence with anidulafungin
Esophageal candidiasis
The efficacy of anidulafungin in treating esophageal candidiasis
was studied in a randomized, double-dummy, controlled clinical
trial that included 601 patients with endoscopically proven
esophageal candidiasis (Krause 2004a) (Table 4). A total of
300 patients received an intravenous loading dose of anidulafungin
100 mg, followed by 50 mg/day, and 301 patients received oral
fluconazole 100 mg/day. Treatment was continued for 14–21 days
(a minimum of 7 days after resolution of symptoms). Of the
504 patients who completed therapy, 242 out of 249 (97.2%) who
received anidulafungin and 252 out of 255 (98.8%) who received
fluconazole demonstrated endoscopic evidence of cure or
improvement, indicating that anidulafungin is at least as efficacious
as fluconazole in the treatment of esophageal candidiasis. The one
difference between treatment groups was the relapse rate. At the
2-week follow-up, the relapse rate was 35.6% for anidulafungin and
10.5% for fluconazole. Although the relapse rate was high with
anidulafungin, a similar relapse rate was also seen in patients with
oropharyngeal candidiasis (OPC) and/or esophageal candidiasis
treated with caspofungin (Arathoon et al. 2002). The cause of this
higher relapse rate associated with echinocandin use when
compared with fluconazole is unknown.
Anidulafungin is also effective in managing patients with
fluconazole-refractory mucosal candidiasis. Anidulafungin was
evaluated in a small, open-label clinical trial in patients with
refractory oropharyngeal or esophageal candidiasis who had
failed at least 14 days’ treatment with fluconazole >200 mg/day
(Vazquez et al. 2007). In an interim analysis of 18 patients enrolled
in the study, 17 had a diagnosis of AIDS (CD4 cell count
<50 cells/mm3). At the end of therapy, 17 out of 18 patients had a
successful clinical response, and 10 out of 11 patients with
esophageal candidiasis were considered endoscopic successes.
Clinical response was defined as cure (absence of symptoms and
requiring no additional therapy), improvement (decrease in
severity when compared to baseline and no further need for
antifungals), or failure. In addition, at the end of therapy, if
patients had esophageal candidiasis at baseline, the
endoscopic response was also evaluated and classified as cure,
improvement, or failure. Furthermore, anidulafungin was well
tolerated with only one serious adverse event (rash).
Anidulafungin appears to be a promising treatment regimen for
azole-refractory mucosal candidiasis.
Candidemia and invasive candidiasis
A phase II, open-label, dose-ranging study was conducted in
123 patients with candidemia and signs or symptoms of active
infection (Krause et al. 2004b) (Table 4). Participants received
anidulafungin at dosages of 50, 75, or 100 mg/day. Success was
defined as both a clinical and microbiological success, as
documented by resolved clinical manifestations and sterilization
of blood cultures. Anidulafungin was successful in 73 out of the
83 evaluable patients at the end of antifungal therapy (84%, 90%,
and 89%, respectively, for the different dosage regimens). At the
2-week follow-up period, the corresponding success rates in
these very ill patients were 72, 85, and 83%, favoring the two
higher dosages. Anidulafungin was well tolerated at all dosages
and adverse events were uncommon. Adverse events considered
to be treatment-related were reported in <5% of patients in any
dose group, with the exception of hypokalemia, which was
reported in 10% of patients in the 50 mg dose group. Overall, the
most commonly reported events were hypotension (13%),
vomiting (13%), constipation (11%), and nausea (11%). There
was no dose–response relationship with respect to the frequency
of adverse events.
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Disease No. patients
enrolled
Treatment and dosage
regimen
Outcome Adverse events Level of
evidence
Reference
Esophageal
candidiasis
36 Afgn 50 mg LD, followed by
25 mg/d
Afgn 70 mg LD, followed by
50 mg/d
Endoscopic response rates
81% vs 85%
N/A 3 Brown et al. 2000
Esophageal
candidiasis
601 Afgn 100 mg LD, followed
by 50 mg/d
Flz 100 mg LD, followed by
100 mg/d
Endoscopic response rates:
242/249 (97%) vs 252/255
(98.8%)
9.3% vs 12% 2 Krause et al. 2004a
Candidemia and
invasive candidiasis
123 Afgn 50 mg/d
Afgn 75 mg/d
Afgn 100 mg/d
Global response rates 72%
vs 85% vs 83%
<5% in all three groups 3 Krause et al. 2004b
Candidemia and
invasive candidiasis
245 Afgn 200 mg LD, followed
by 100 mg/d
Flz 800 mg LD, followed by
400 mg/d
Global response rate at end
of i.v. 75.6% vs 60.2%
Comparable in both
groups
2 Reboli et al. 2007
Antifungal-refractory
mucosal candidiasis
19 Afgn 200 mg LD, followed
by 100 mg/d
Clinical response 18/19
Endoscopic response 11/12
Nausea/vomiting ~20%
Hypokalemia ~10%
3 Vazquez et al. 2007
Afgn, anidulafungin; d, day; Flz, fluconazole; i.v., intravenous; LD = loading dose; N/A, not available.
Table 4 | Clinical trials evaluating anidulafungin in candidemia and esophageal candidiasisIn a recently completed phase III, multicenter, double-blind,
randomized clinical trial, a 100 mg dose of anidulafungin was
compared with a 400 mg dose of fluconazole in patients with
candidemia and/or invasive candidiasis (Reboli et al. 2007)
(Table 4). A total of 261 patients were enrolled in this pivotal clinical
trial, 256 were included in the intent-to-treat population, and
245 in the modified intent-to-treat population. In the study
127 patients received at least one dose of anidulafungin while
118 patients received fluconazole. The primary analysis was
performed at the end of intravenous therapy (day 10). Success
was defined as both a clinical and microbiological success, as
documented by resolved clinical manifestations and sterilization of
blood cultures. A successful outcome was achieved in 76% of
patients who received anidulafungin compared with a 60%
success in patients who received fluconazole. The difference
between groups was 15.4%, with a 95% confidence interval of 3.9
to 27.0. Additionally, at the 2-week follow-up period, a similar
treatment difference in response was observed, with a success
rate of 65% and 49%, respectively. Compared with those subjects
who received fluconazole, anidulafungin recipients had a higher
rate of success for every Candida species except for
C. parapsilosis. However, the total number of patients with
C. parapsilosis was only 24 (10%) of the total population
(10 patients in the anidulafungin arm and 14 patients in the
fluconazole arm), thus making it difficult to make any definitive
comments regarding the treatment differential. In addition, it was
not a statistically significant difference. One of the limitations to
this study was associated with the fact that the evidence for
superiority of anidulafungin over fluconazole was decreased when
data from the highest enrolling site were excluded from the
analysis. However, statistical analysis was not able to demonstrate
a “center effect,” and global success rates were 73% in the
anidulafungin arm compared with 61% in the fluconazole arm
(treatment difference of 12.1%; 95% CI –1.1, 25.3).
Overall, the adverse event and tolerability profiles were similar
between the two treatment groups. Treatment-related adverse
events were only observed in two patients in each arm, with one
case of seizures and one case of atrial fibrillation in the
anidulafungin arm. In general, most of the adverse events
reported were due to the underlying disease state and not the
study drugs. In addition, the mortality rate from all causes was
found to be 31% in the fluconazole arm compared with 23% in
the anidulafungin arm. Although it was an 8% difference, it did not
reach statistical difference.
Safety
In clinical studies documenting over 600 patients, anidulafungin
has been well tolerated compared with adverse effects seen with
other antifungals. The most common adverse effects reported
include headache and nausea. In a few cases mild, reversible
elevations of liver function tests have been seen. With rapid
intravenous administration some flushing, nausea, and dyspnea
were reported; however, infusion-related reactions quickly subside
and can be greatly reduced with slower infusion rates. No specific
monitoring parameters are routinely recommended in patients
receiving anidulafungin (Krause et al. 2004ab; Reboli et al. 2007).
Drug interactions
In studies performed to date, anidulafungin has not been
associated with any significant drug–drug interactions. Concurrent
dosing with cyclosporine (a CYP3A4 substrate) following
anidulafungin 100 mg/day demonstrated no significant alteration in
pharmacokinetics of either drug (Dowell et al. 2005). No changes in
disposition were observed with concomitant administration of
anidulafungin and voriconazole (Dowell et al. 2005) and liposomal
Amphotericin B. Similarly, no interactions have been identified
between anidulafungin and any substrates, inhibitors, or inducers
of cytochrome P450 enzymes, including rifampin, efavirenz,
or nevirapine.
While few postmarketing data have been published on the safety of
anidulafungin, a small study provides information on the potential
for disulfiram-like reaction when anidulafungin and its alcohol-
containing diluent is administered with concomitant metronidazole.
A prospective cohort was followed for potential disulfiram-like
reaction, defined as having at least one symptom from each
category of general disorder, gastrointestinal, and neurologic
symptoms. Of 44 patients receiving the combination of agents,
none experienced a disulfiram-like reaction (Hurren et al. 2007).
Economic evidence and resource utilization
The treatment of candidemia has been associated with an
attributable cost of nearly $US40 000 per case and greater than
10 additional days of hospitalization (Zaoutis et al. 2005).
There is no economic evidence for the use of anidulafungin over
other echinocandins or azoles in the treatment of candidemia and
or invasive candidiasis. However, the fungicidal activity in vitro of
anidulafungin compared with the fungistatic activity of the azoles,
and the fact that the pivotal candidemia trial demonstrated
statistical superiority of anidulafungin over fluconazole along with
a decrease in mortality, suggest that the use of anidulafungin over
fluconazole in patients with candidemia may prove beneficial.
Cost-benefit and cost-effectiveness studies still need to be done
comparing these two classes of antifungals.
Dosage, administration, and formulations
The FDA-approved dose of anidulafungin is based on the
indication. For esophageal candidiasis, it is given as a 100 mg
intravenous loading dose, followed by 50 mg intravenously once
daily. For the treatment of candidemia and systemic candidiasis,
a 200 mg loading dose is given on day one, followed by 100 mg
daily. Clinical need for dose escalation has not been reported, but
a one-time dose of 260 mg, the maximum dose studied, was well
tolerated (Thye et al. 2001). The maximum cumulative dose in
studies without additional adverse effects reported was daily
doses of 100 mg continued over 90 days (Dowell et al. 2004).
Unlike other echinocandins, no adjustments of anidulafungin
doses are necessary for either renal or hepatic insufficiency. The
drug is a large molecule and is not well dialyzable; however,
specific dosing recommendations in dialysis or continuous renal
replacement therapy have not been established.
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Like other currently available echinocandins, anidulafungin is
available only in intravenous preparations, owing to its large
molecular weight and low oral bioavailability. Anidulafungin is
insoluble in water, and is reconstituted in 20% w/w dehydrated
alcohol in water for intravenous administration. After
reconstitution in the manufacturer-provided solution, it can be
diluted with either 0.9% sodium chloride or 5% dextrose and
should be administered within 24 hours. A maximum infusion rate
of 1.1 mg/minute is recommended to reduce the likelihood of
infusion-related reactions.
Place in therapy
The safety and efficacy of anidulafungin, plus its novel
pharmacokinetics, make it a suitable alternative antifungal for
therapy of mucocutaneous candidiasis, candidemia, and invasive
candidiasis. It provides a broad spectrum of activity with proven
efficacy against a wide array of Candida species, including those
that are azole- or polyene-resistant, and has also demonstrated
activity against Aspergillus species.
Anidulafungin appears to have several advantages over other
antifungal drugs. For example, it does not require dosing
adjustments in patients based on age, gender, weight, disease
state, concomitant drug therapy, or renal or hepatic insufficiency.
In addition, because of its lack of hepatic metabolism and lack of
P450 interaction, it does not have any drug–drug interactions.
Furthermore, because of its unique mechanism of action,
anidulafungin does not induce cross-resistance with other
classes of antifungals.
It is the first antifungal agent that has demonstrated statistical
superiority in a comparative clinical trial evaluating therapy for
candidemia. Results of current studies warrant further clinical
trials evaluating the use of anidulafungin as either primary or pre-
emptive therapy for invasive fungal infections, such as
candidemia and invasive candidiasis and aspergillosis. Moreover,
because of its lack of adverse drug interactions and the possibility
of in-vitro additive or synergistic activity with other antifungals,
the role of anidulafungin in combination with other antifungals
should be further explored in the management of some of the high
mortality-associated mold infections, such as aspergillosis.
In summary, anidulafungin shows excellent promise and should
be a valuable new antifungal agent with a novel mechanism of
action. Completed clinical studies have demonstrated that
anidulafungin should prove useful as a first-line agent for treating
a range of serious fungal infections, including mucocutaneous
candidiasis, candidemia, invasive candidiasis, and azole-
refractory mucosal candidiasis. However, although it has in-vitro
activity against Aspergillus species and other molds, its
usefulness against serious mold infections such as aspergillosis,
either as monotherapy or in combination, is currently unknown.
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